Patients With RA May Safely Receive ICIs for Cancer Treatment
Researchers studied the effect of preexisting rheumatoid arthritis on risk for mortality and immune-related adverse events among those receiving immune checkpoint inhibitors.
Researchers studied the effect of preexisting rheumatoid arthritis on risk for mortality and immune-related adverse events among those receiving immune checkpoint inhibitors.
Researchers sought to determine physician preferences for treating patients with relapsed/refractory diffuse large B-cell lymphoma in the third line setting.
Researchers sought to determine whether there were subgroups of patients with DLBCL who would benefit from adding bortezomib to R-CHOP.
The withdrawal of MCL and MZL indication does not affect the other approved indications for Imbruvica.
Researchers sought to determine the role of certain genetic variants as biomarkers in primary central nervous system lymphoma.
Survivors of childhood cancer may experience a range of late effects more than 15 years after diagnosis, a new study suggests.
Pembrolizumab plus ICE chemotherapy appears effective as second-line treatment in patients with transplant-eligible Hodgkin lymphoma.
Research presented at the 2023 Tandem Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR demonstrated favorable results for various types of lymphoma.
Researchers sought to determine whether valemetostat would be safe and effective in patients with relapsed/refractory adult T-cell leukemia/lymphoma.
Researchers sought to determine which genetic variants could be linked with the predisposition for developing Hodgkin lymphoma.